Competition policy essential for access to medicines, says European trade group

29 January 2019

Medicines for Europe welcomes the publication of the European Commission Report on Competition Enforcement in the Pharmaceutical Sector (2009-2017).

This compilation of pharmaceutical competition law cases is part of the Health Council Conclusions of June 2016 on strengthening the balance in the pharmaceutical systems in the European Union. These conclusions aim to ensure the timely availability of generic and biosimilar medicines for patient access and sustainable pharmaceutical budgets, says Medicines for Europe, which represents biosimilars and generic drugmakers.

The report provides valuable information on how to prevent unnecessary and unlawful delays to generic and biosimilar medicines competition. Competition law scrutiny is essential to prevent misuse of the regulatory system to delay competition including the spread of misleading information to denigrate generic and biosimilar medicines in the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK